Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06808334 · ClinicalTrials.gov registry record
CLAiR Pivotal Study
A clinical trial of No Condition, sponsored by Toku Eyes.
- Recruiting
- Registry status
- 942
- Enrollment target
- 1
- Study location
NCT06808334: Recruiting study of No Condition, sponsored by Toku Eyes.
NCT06808334 is a study of No Condition that is actively recruiting participants, run by Toku Eyes. The registered enrollment target is 942 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06808334, a study of No Condition, is actively recruiting participants, sponsored by Toku Eyes.
- RECRUITING
- Registry status
- 942 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-site, observational clinical study to validate the performance of the CLAiR AI software in identifying elevated atherosclerotic cardiovascular disease (ASCVD) risk from retinal (eye) images obtained from two different retinal image camera models.
Primary Outcome
Sensitivity and Specificity of CLAiR binary elevated risk classification (PCE ≥ 7.5% Y/N) against the reference standard of PCE ≥ 7.5%
Conditions Studied
Interventions
- OTHER CLAIR
Study Locations (1)
Ohio
- Diabetes and Endocrine Associates of Stark County - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 942 participants |
| Start Date | 2025-02-27 |
| Est. Completion | 2025-10-01 |
What NCT06808334 shows while recruiting
NCT06808334 is an observational study that tracks outcomes without assigning an intervention. The registered 942 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with No Condition appearing as the primary indexed condition, and to 1 intervention - of which CLAIR is the first listed.
NCT06808334 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06808334 about?
NCT06808334 is a clinical study titled "CLAiR Pivotal Study". This is a multi-site, observational clinical study to validate the performance of the CLAiR AI software in identifying elevated atherosclerotic cardiovascular disease (ASCVD) risk from retinal (eye) images obtained from two different retinal image camera models.
What is the current status of trial NCT06808334?
This trial is currently recruiting. The enrollment target is 942 participants. The study started on 2025-02-27. Estimated completion is 2025-10-01.
What conditions does trial NCT06808334 study?
This clinical trial studies the following conditions: No Condition.
What interventions are being tested in trial NCT06808334?
The interventions under investigation include: CLAIR (OTHER).
Who is sponsoring clinical trial NCT06808334?
This trial is sponsored by Toku Eyes, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06808334 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for No Condition
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI